Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 39

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 39
---
A Investors purchase the Second Initial Promissory Notes, in the aggregate principal amount of $1.944 million,
for a purchase price of $1.750 million. Commencing on the date that is three months after the Second Initial Closing, we may request,
at our sole discretion, that the CLA Investors purchase additional Promissory Notes in the aggregate principal amount of $2.5 million
for a purchase price of $2.25 million during each subsequent three month period such that the aggregate principal amount of such additional
Promissory Notes is $7.5 million for a purchase price of $6.75 million. We are registering up to 16,970,241 common shares, issuable upon
conversion of Initial Promissory Notes in the aggregate principal amount of $2.5 million issued or issuable pursuant to the SPAs, to permit
the resale of the Note Shares by the CLA Investors from time to time after the date of this prospectus.

Each selling shareholder of
the securities and any of their pledgees, assignees and successors-in-interest may, from time to time, sell any or all of their securities
covered hereby on the principal trading market of our common shares or any other stock exchange, market or trading facility on which the
securities are traded or in private transactions. These sales may be at fixed or negotiated prices. A selling shareholder may use any
one or more of the following methods when selling securities:

| ● | ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;                                                                                    |
| ● | block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; |
| ● | purchases by a broker-dealer as principal and resale by the broker-dealer for its account;                                                                                          |
| ● | an exchange distribution in accordance with the rules of the applicable exchange;                                                                                                   |
| ● | privately negotiated transactions;                                                                                                                                                  |
| ● | settlement of short sales;                                                                                                                                                          |
| ● | in transactions through broker-dealers that agree with the Selling Shareholders to sell a specified number of such securities at a stipulated price per security;                   |
| ● | through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;                                                       |
| ● | a combination of any such methods of sale; or                                                                                                                                       |
| ● | any other method permitted pursuant to applicable law.                                                                                                                              |

The